“That is my role a lot of times,” Follett said. “I can speak geek with the scientists, but I also understand the language of the law.”
The road to her practice was a natural one, but not quite what she expected. While completing her studies, Follett originally had designs on being a professor.
“About my fourth year in, I realized that wouldn’t be a good fit,” she said. “I started to look at other fields that apply the things I like to do. I like to write, I like to talk to people, I like to teach.”
Follet mainly represents startups in the life science, pharmaceutical and chemical industries. While bringing to bear her scientific expertise, she also understands the significance of a well-executed patent strategy in helping the development of innovative treatments.
In recent years, she played a key role in the worldwide patent strategy for Loxo Oncology, a company developing precision medicines for genetically defined cancers. She also worked on the company’s patent/financial diligence related to a $1.5 billion deal with Bayer in November 2017, as well as multiple financial offerings that year that resulted in $380 million being raised. Early this year, Loxo was acquired by Eli Lilly for $8 billion in cash.
“They were doing amazing work, and it was rewarding to be a part of their success,” she said.
Like this article? Gain access to all of our great content with a month-to-month subscription. Start your subscription here.